DMPA can cause bone loss in adolescent females.
After 2 years, adolescent girls using depot medroxyprogesterone acetate (DMPA) as their form of contraception had lower bone mineral density (BMD) determinations at the spine and femoral neck than girls using oral contraceptives (OCs) or neither forms of birth control, according to the results of an observational, prospective, cohort study.
Researchers included 433 postmenarcheal girls between the ages of 12 and 18 years. Over 2 years, mean percentage change in spine BMD for girls taking DMPA, OCs, or neither was –1.5%, +4.2%, and +6.3%, respectively. Mean percentage change in BMD at the femoral neck was –5.2%, +3.0%, and +3.8%, respectively.
Most of the decrease in BMD seen with DMPA occurred during the first year of use and then slowed during the second year. Decreases in BMD never approached a range consistent with osteopenia.
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More
Study shows hormone therapy offers lasting benefits for women over 65
September 12th 2024A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.
Read More